Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 36
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
12/1/2001
 
First Published:
11/1/1997
1.
Phase II/III Diagnostic Study of Whole Body Fludeoxyglucose F 18 Positron Emission Tomography to Measure the Response to Induction Chemotherapy of Potentially Resectable Lung and Esophageal Carcinomas (Summary Last Modified 12/2001)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Diagnostic
Closed
18 and over
NCI
MSKCC-96079
NCI-G97-1334, NCT00002930
Last Modified:
4/30/2007
2.
Phase II/III Diagnostic Study of C11-Methionine and 2-F18-Fluoro-2-deoxy-D-Glucose (FDG) Positron Emission Tomography (PET) Imaging in Patients With Progressive Prostate Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Diagnostic
Closed
Not specified
NCI
MSKCC-97007
NCI-G97-1232, NCT00002981
Last Modified:
12/14/2007
 
First Published:
11/22/2006
3.
Phase II/III Study of Multimodality Breast Imaging Comprising Digital Mammography, Ultrasound, MRI, and Positron Emission Tomography in Women With Newly Diagnosed Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Diagnostic
Completed
18 and over
NCI
UPCC-12199
UPCC-414500, NCT00194337
4.
Utility of FDG-PET Scan on the Selection of Patients for Resection of Hepatic Colorectal Metastases
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Diagnostic, Treatment
Completed
18 to 75
Other
POLEM (ZonMW DO 945-11017)
(ZonMW DO 945-11017), NCT00119899
5.
Usefulness of FDG-PET for Advanced Cervical Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Diagnostic
Closed
no age specified
Other
CTRP024
NSC 92-2314-B-182A-084, NCT00146458
6.
PET Imaging to Determine the Role of PET in the Assessment of Regional Disease in Breast Cancer (PET PREDICT Trial)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Diagnostic
Completed
18 and over
Other
CTA-Control-092493
NCT00201942
7.
PET and MRI in the Follow-up of Neoadjuvant Chemotherapy of Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Diagnostic
Closed
18 and over
Other
P020907
AOR02072, NCT00236275
8.
Predictive Value of FDG-PET-CT Scans for Patients With Lung Cancer Receiving Concurrent Chemo-Radiation
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Diagnostic, Treatment
Temporarily closed
18 and over
Other
06-02-117
TACIR, NCT00522639
Last Modified:
8/22/2008
 
First Published:
7/6/2007
9.
Phase I/II Study of Neoadjuvant Chemoradiotherapy Comprising Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Followed by Surgical Resection and Consolidation Therapy Comprising Erlotinib Hydrochloride in Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Biomarker/Laboratory analysis, Diagnostic, Treatment
Temporarily closed
18 and over
NCI, Pharmaceutical / Industry
CCCWFU-60106
CCCWFU-IRB00000695, SANOFI-AVENTIS-OX-05-013, CCCWFU 60106, NCT00499564
Last Modified:
7/12/2008
 
First Published:
10/31/2007
10.
Phase I/II Study of Everolimus, Temozolomide, and 3D-Conformal Radiotherapy or Intensity-Modulated Radiotherapy Followed by Adjuvant Temozolomide With or Without Everolimus in Patients With Newly Diagnosed Glioblastoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Biomarker/Laboratory analysis, Treatment
Temporarily closed
18 and over
NCI
NCCTG-N057K
N057K, NCT00553150
Select All on One Page
1
2
3
4
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute